News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bristol-Myers Squibb (BMY) Release: Opdivo (Nivolumab) Demonstrates Superior Recurrence-Free Survival Versus Yervoy (Ipilimumab) For Patients With Resected High-Risk Melanoma In Phase III Checkmate -238 Study



9/11/2017 7:36:49 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Opdivo decreased the risk of disease recurrence by 35% compared to Yervoy

Opdivo is the first anti-PD-1 to improve RFS and only I-O therapy to demonstrate superiority versus an active control in this patient population

Adjuvant treatment with Opdivo was well tolerated, with 14% of patients experiencing grade 3/4 adverse events and 10% discontinuing due to toxicity

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that treatment with Opdivo (nivolumab) 3 mg/kg resulted in a significant improvement in recurrence-free survival (RFS) compared to Yervoy (ipilimumab) 10 mg/kg in patients with stage IIIb/c or stage IV melanoma following complete surgical resection. Following the July 5 announcement of topline results, detailed findings from the phase 3 CheckMate -238 study will be highlighted on September 11 during the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain as part of the press program at 8:15 a.m. CEST and in Presidential Symposium 3 (LBA8) at 4:30 p.m. CEST. The results are also being published simultaneously in the New England Journal of Medicine.

At this planned interim analysis, Opdivo met its primary endpoint, showing a statistically significant improvement of 35% in RFS (HR 0.65; 97.56% CI: 0.51 to 0.83; p <0.0001) compared to Yervoy. The 18-month RFS rates for the Opdivo and Yervoy groups, respectively, were 66.4% (95% CI: 61.8 to 70.6) and 52.7% (95% CI: 47.8 to 57.4). Median RFS had not yet been reached for either group at the time of this analysis. This benefit was consistent across key subgroups, including BRAF mutated and BRAF wildtype patients, and no new safety signals were identified in this trial.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES